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Abstract An 81-year-old male and a 47-year-old female
experienced recurrent severe bullous dermatosis secondary
to an intake of drugs and alternative medicines indicated
for arthralgias. The first patient had previously presented
with Stevens–Johnson/toxic epidermal necrolysis (TEN)
overlap syndrome in 2007 secondary to ingestion of
trimethoprim/sulfamethoxazole indicated for a urinary tract
infection; 6 years later, he presented with the same syn-
drome 2 days after ingestion of oral naproxen tablets
250 mg twice daily. The second patient had presented
5 years previously with TEN after receiving trimetho-
prim/sulfamethoxazole. In 2014, she presented with
arthralgias and received a xenobiotic oral called ‘miracle
pills’ (dosage is unknown); 3 weeks later, she again
experienced TEN. Both patients were treated with intra-
venous immunoglobulin 400 mg/kg/day; duration of
treatment was 5 days for the first patient and 3 days for the
second. However, the male patient died from severe sepsis;
the female patient experienced a favorable outcome. There
are many risk factors for the development of cutaneous
adverse drug reactions; a history of allergic reactions is one
important risk factor, and both patients had it. This article
reviews the scientific literature on this topic and analyzes
the possible causes, including infectious processes,
immunological defects, and immunogenetic factors.
Key Points
Stevens–Johnson syndrome and toxic epidermal
necrolysis can be recurrent for different drugs.
History of adverse drug reactions is an important risk
factor for the development of hypersensibility to
medication.
Alternative medicine can produce cutaneous severity
reactions.
Introduction
Stevens–Johnson syndrome (SJS) and toxic epidermal
necrolysis (TEN) or Brocq–Lyell syndrome are dermatoses
triggered principally by drugs [1]. Cases reported as recurrent
have been attributed to infectious or environmental factors
[2]. However, most cases in the pediatric population are not
related to recurrences secondary to drug intake. Demonstrat-
ing the causal medication with certainty is complex [3].
We present two cases. The first was a man with TEN
secondary to naproxen intake in whom sulfonamides had
previously triggered the same syndrome. The second was a
woman with a history of SJS after ingesting sulfonamides
and who presented, in her most recent hospitalization, with
TEN triggered by alternative medicines.
Clinical Cases
Patient 1
The patient was male, 81 years old, and had a 30-year
history of alcoholism. He presented with overlapping SJS/
& Claudia Reynoso-von Drateln
vondrateln02@yahoo.com.mx
1 High Specialty Medical Unit, National Medical Center,
Specialities Hospital, Belisario Domı´nguez nu´m. 1000. Col.
Independencia Oriente, CP 44340 Guadalajara, Jalisco,
Me´xico
Drug Saf - Case Rep (2016) 3:9
DOI 10.1007/s40800-016-0032-x
TEN syndrome in 2007 secondary to ingestion of
trimethoprim/sulfamethoxazole indicated for a urinary tract
infection. In that instance, he required hospitalization for
1 week and was discharged to his home. This time, 6 years
later, he presented with the same syndrome 2 days after
ingestion of oral naproxen tablets 250 mg twice a day
indicated as an analgesic.
He was admitted to our hospital unit with dermatosis
affecting 20 % of his body surface manifesting as flaccid
blisters on an erythematous base, a positive Nikolsky sign,
conjunctivitis, and ulcers in the oral mucosa (Fig. 1). He
had a Score of Toxic Epidermal Necrosis (SCORTEN)
score of 4 points. He presented with signs and symptoms of
sepsis, hyperglycemia, and elevated ureic nitrogen. He was
treated with intravenous immunoglobulin (400 mg/kg/day
completing a 5-day course); however, on hospital day 15,
he developed multiple organ failure and unfortunately died.
Patient 2
Patient 2 was a 47-year-old female with a history of
oophorectomy at the age of 17 years for left ovarian ter-
atoma, rheumatoid arthritis, lupus erythematosus,
fibromyalgia, and dry eye diagnosed 8 years previously.
She had a history of TEN 5 years ago triggered by
trimethoprim/sulfamethoxazole without apparent sequelae.
She received methotrexate 7.5 mg/week, prednisone
5 mg/day, chloroquine 200 mg/day, and sulfasalazine
500 mg/day before hospitalization.
Her symptoms began 3 weeks after she had taken a
xenobiotic called ‘miracle pills’ indicated for arthralgia
(this type of medication is used in alternative therapy).
Symptoms started with pruritus and erythema in the lumbar
region that extended to 75 % of the body surface; blisters
appeared later. We do not know what dose of the medi-
cation she received, and we suspended treatment as soon as
we diagnosed the adverse drug reaction.
Nikolsky’s sign was detected on admission, along with
friable skin and large areas of denudation with involvement
of the ocular and buccal mucosa. A diagnosis of TEN was
made. Treatment was started with intravenous methyl-
prednisolone 80 mg/day for 10 days and intravenous
immunoglobulin 400 mg/kg/day for 3 days. Surgical
cleanings were performed in the burn unit. She entered
remission of mucocutaneous lesions within 7 days and was
discharged to her home 15 days after admission to hospital.
Discussion
SJS and TEN are rare diseases that occur in approximately
two cases per million inhabitants per year; however, they
have a considerable effect on the public health of any
country because of their high mortality rate, which ranges
between 20 and 25 % [4]. Recurrent disease is even rarer
and has been reported more frequently in the pediatric
population.
Various articles in the scientific literature have reported
recurrent disease for SJS and TEN (Table 1). Brown et al.
[3] reported a case of SJS with three episodes of recurrence
in an adult, apparently secondary to a monomeric non-ionic
contrast medium called lopromide.
Casselman et al. [5] reported the case of an 11-year-old
girl with recurrent SJS, with seven episodes over a period
of 8 years associated with Mycoplasma or a viral infection
secondary to dysfunction of the innate immune system,
particularly natural killer (NK) cells.
Finkelstein et al. [6] reported ten children with recurrent
SJS from a total of 55 study subjects (18 % of the total
pediatric population studied).
The etiopathogenic mechanisms that could explain why
a patient presents with this skin disease on more than one
occasion are unknown. However, it is possible that medi-
cations with very similar stereochemical structures
administered to the same patient may trigger recurrent SJS
or TEN. This may occur because cross-reactivity triggers
mechanisms of hypersensitivity to the causal antigen. On
the other hand, we consider the possibility that recurrent
infections in patients with immune dysfunction or possible
primary immunodeficiency and immune-inflammatory
responses against microbial agents, such as the Herpes
simplex type virus and bacteria such as MycoplasmaFig. 1 Toxic epidermal necrolysis
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pneumoniae, may explain the phenomenon of attack on the
stratum corneum cells within the skin [5]. The other pos-
sibility concerns the use of medications that act as super-
antigens, non-covalently bind to T-lymphocyte receptors
and/or the histocompatibility molecules, and trigger the
immune system per se without prior sensitization, implied
by the recently proposed p–i concept (pharmacological
interaction with immune receptors) [7]. Another etio-
pathogenic possibility that explains the recurrence of this
type of blistering disease is the immunogenetic variability
that all human beings have, such as Asian patients who
carry the haplotype HLA-B*1502, which is associated with
a 100 % risk for presenting with SJS secondary to carba-
mazepine [8]. Finally, it is important to mention the hepatic
detoxification system, including the cytochrome P450
(CYP) enzyme complex. This may be responsible for
producing certain drug metabolites that influence the
recurrence of SJS and/or TEN, as is the case with the
hepatotoxic product N-acetyl-p-benzoquinoneimine from
acetaminophen [9].
Our hypothesis regarding the recurrence of the above
syndromes in our patients is as follows. Patient 1 ingested
naproxen prior to the second event. This drug is metabo-
lized by CYP2C, and it is well known that the activity of
the CYP complex decreases as humans get older. It has
been mentioned that one factor influencing the great
diversity of responses to medications is changes in the
immunogenetics of the CYP complex [10]. On the other
hand, people aged [60 years present a higher risk of
adverse drug reactions because they often ingest more than
one medication, have relatively more fat for storage, their
kidneys are less able to excrete drugs in the urine, and their
liver less effectively metabolizes many medications [11].
Patient 2 had a history of hypersensitivity to trimetho-
prim/sulfamethoxazole and presented with the skin reac-
tion following the ingestion of an alternative therapy. It is
possible that the xenobiotic contained chemical products
similar to the previous antibiotic and the immune system
triggered an inflammatory response against stratum cor-
neum cells as a result of a cross-reaction; however, we
were unable to confirm this.
This case report represents the first Mexican experience
and an addition to the few studies we could find, as shown
in Table 1. The prevention of recurrent attacks depends on
identifying the cause of the first immune–inflammatory
attack on the dermoepidermal cellular target. It is important
to note that any patient who has had a previous hyper-
sensitivity reaction to drugs is at high risk for recurrence of
these syndromes and therefore represents an immune
etiopathogenic challenge; our obligation will be to avoid
subsequent clinical episodes. The study of immunomolec-
ular and immunogenetic markers to determine the risk of
adverse drug reactions constitutes a line of research that
has not yet been consolidated and that, once implemented,
could reduce morbidity and mortality in our patients.
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Study Patients (N) Age of presentation (years) Association
Daubeney and Scopes [2] 1 11, 12 Mycoplasma pneumoniae
Hartel et al. [11] 1 5, 16 Winter
Brown et al. [3] 1 37 Lopromide contrast
Casselman et al. [5] 1 11 Natural killer cells dysfunction
Campagna et al. [12] 1 12 M. pneumoniae
Finkelstein et al. [6] 10 1. 8/13/15 1. M. pneumoniae
2. 10/13 2. M. pneumoniae
3. 14/17 3. Herpes simplex
4. 15/21 4. Carbamazepine/zonisamide
5. 10.6/10.8 5. M. pneumoniae/H. simplex
6. 14/15 6. Phenytoin/lamotrigine
7. 11/12.7 7. M. pneumoniae
8. 11/12.5 8. M. pneumoniae
9. 14.3/14.7 9. M. pneumoniae/amoxicillin
10. 14.5/14.8 10. Lamotrigine/unknown
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